DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two ...

Tirzepatide glaucoma risk was lower than with selective glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus ...

Please provide your email address to receive an email when new articles are posted on . Decreases in mental health scores after glaucoma diagnosis may be associated with fears of vision loss or ...

Please provide your email address to receive an email when new articles are posted on . The American Optometric Association has released a new, evidence-based clinical practice guideline draft, “Care ...

A risk score incorporating genetic variants for open-angle glaucoma is accurate enough to help with diagnosis of the condition, an interim study reveals. Although hundreds of genetic changes are ...

Primary open-angle glaucoma (POAG) is among the leading causes of irreversible blindness. Early detection and treatment are crucial for vision preservation, and research to identify genes associated ...

In patients without diabetes diagnosed with overweight or obesity, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) led to a greater reduction in the risks for primary open-angle ...

Open-angle glaucoma often has no symptoms until vision loss begins, so regular screening is important. You can use eye drops and laser therapy to slow the progression of open-angle glaucoma. Try using ...

(Dr. Rita Dash) Glaucoma has a reputation as the "silent thief of sight," and for good reason. It is one of the leading ...